Myeloma cells express increased levels of PD-L1 [120], and as such, PD-1/PD-L1-targeting therapy should be ideal for patients with MM, but PD-1 blockade has not displayed any relevant clinical effect in MM [119]. This evidence concerns the gene CD274 and Miyoshi myopathy.